Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending June 10, 2003. The report details specific corporate actions regarding share re-purchases executed in accordance with shareholder authority granted at Annual General Meetings in May 2002 and May 2003.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to specific share buyback transactions:
- Transaction 1 (May 15, 2003): 1,100,000 Ordinary 25 pence shares purchased for cancellation at 1,302.5722 pence per share.
- Transaction 2 (June 9, 2003): 1,100,000 Ordinary 25 pence shares purchased for cancellation at 1,249.692 pence per share.
Material Changes
The filing does not report material changes in operating results or financial position compared to prior periods. The primary activity reported is the reduction of the company's share capital through the cancellation of 2,200,000 shares in total during the reporting window.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. The document is strictly a notification of share re-purchase activities.
Investor Verification Checklist
- Verify the total number of shares authorized for re-purchase under the May 2002 and May 2003 shareholder resolutions.
- Confirm the remaining balance of the share buyback program following these two transactions.
- Review the company's full interim or annual financial reports for comprehensive revenue and profit data, as this filing does not contain them.